Author(s): Raposo, I. ; Bettencourt, A. ; Leite, L. ; Selores, M. ; T, Torres
Date: 2019
Persistent ID: http://hdl.handle.net/10400.16/2350
Origin: Repositório Científico da Unidade Local de Saúde de Santo António (ULSSA)
Subject(s): Biological Products/therapeutic use; Psoriasis/drug therapy; Ustekinumab/therapeutic use; Biológicos/uso terapêutico; Psoríase/tratamento; Ustekinumab/uso terapêutico
Ustekinumab is a monoclonal antibody directed against the p40 subunit common to both IL-12 and IL-23 cytokines. Although the evidence of ustekinumab efficacy and safety in clinical trials is extensively recognized, data on its use in clinical practice is limited. Our objective is to report on the real-life experience of two Portuguese dermatology departments with ustekinumab in patients with moderate to severe psoriasis, and to identify the clinical characteristics associated with a weaker clinical response.
